Akeso Biopharma, an innovative biotechnology company, announced that it has raised nearly US$150 million in a series D funding round led by private equity firm Loyal Valley Capital (LVC) and Chinese pharmaceutical firm Sino Biopharmaceutical Limited.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
